ATMP Europe recommended approval of five drugs at its November meeting

At its November meeting, the European Medicines Agency's Human Medicines Committee (CHMP) recommended approval of five drugs for market.
CHMP recommends that Phesgo (pertuzumab/trastuzumab) be used to treat early and metastasis HER2-positive breast cancer patients.
Phesgo is a fixed dose combination of HER djubial inhibitors Pertuzumab and HER2 monoantigen Herceptin (trastuzumab) and hyalurase, injected under the skin.
photo source: Roclanda (latanoprost/netarsudil) eye drops are recommended to reduce elevated in-eye pressure (IOP) in primary open-angle glazing or high-eye pressure adult patients.
photo source: Baloxavir marboxil is recommended for the treatment of simple influenza aged 12 and over.
also recommends that Roche's oral antiviral drug be approved to prevent influenza in people 12 years of age and older.
Photo Source: It is recommended that anti-VEGF monoantigen Onbevzi (Roche Beva monoantigen) be used to treat colorectal cancer, breast cancer, non-small cell lung cancer, renal cell carcinoma, ovarian epithelial cancer, fallopian tubes, primary peritronal cancer and cervical cancer.
photo source: CHMP recommends using tagraxofusp, a cytotoxin targeted at CD123, for the treatment of bullet-like plasma cell-like dendroid cytoblastoma (BPDCN).
picture source: